Design and evaluation of antigen-specific vaccination strategies against cancer

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 576-582

  Offringa, Rienk ^a   Van Der Burg, Sjoerd H ^a   Ossendorp, Ferry ^a   Toes, Rene EM ^a   Melief, Cornelis JM ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; CARCINOEMBRYONIC ANTIGEN; CD4 ANTIGEN; CELL ADHESION MOLECULE; EPITOPE; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ONCOPROTEIN; PROTEIN P53; TUMOR ANTIGEN; TYROSINASE RELATED PROTEIN 2; VACCINE;

CLINICAL TRIAL; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; HELPER CELL; HUMAN; IMMUNE RESPONSE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW; VACCINATION;

EID: 0033811967     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00145-X     Document Type: Review

References (61)

1. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
2. Cell-based vaccination against melanoma - Background, preliminary results, and perspective
3. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
4. Strategies for immunotherapy of cancer
5. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
6. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
7. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma
8. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
9. A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
10. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression
11. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer
12. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7
13. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma
14. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts
15. Cross-tolerance: A pathway for inducing tolerance to peripheral tissue antigens
16. + T cell tolerance to peripherally expressed antigens
17. Autoaggression and tumor rejection: It takes more than self-specific T-cell activation
18. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus
19. Specific cytolytic T cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine
20. Coupling and uncoupling of tumor immunity and autoimmunity
21. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
22. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
23. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
24. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma
25. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells
26. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes
27. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire
28. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide
29. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck
30. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
31. Peptide-based cancer vaccines
32. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
33. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization
34. Genetic immunization against neu/erbB2 transgenic breast cancer
35. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice
36. Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer
37. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors
38. Immune selection after antigen-specific immunotherapy of melanoma
39. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion
40. Harnessing self-reactivity in cancer immunotherapy
41. Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells
42. Flanking residues alter antigenicity and immunogenicity of multi-unit CTL epitopes
43. An autologous oral DNA vaccine protects against murine melanoma
44. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen
45. Immune response to a differentiation antigen induced by altered antigen: A study of tumor rejection and autoimmunity
46. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals
47. HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS
48. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines
49. Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
50. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
51. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376
52. Cutting edge: Rapid cloning of tumor-specific CTL suitable for adoptive immunotherapy of melanoma
53. Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papiliomavirus antigens
54. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes
55. An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillance in metastatic lesions
56. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions
57. Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses
58. In situ detection of virus and tumor-specific T cell immunity
59. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes
60. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2
61. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial